Thomas Seisen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas Seisen has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
M. Rouprêt
9 shared publications- Pierre Colin
Urology Department, La Louvière, 59042 Lille, France
5 shared publications B. Peyronnet
4 shared publications- Eva Compérat
Academic Department of Pathology, Hôpital Tenon, AP-HP, UPMC University Paris 06, 75020 Paris, France
4 shared publications S. Shariat
4 shared publications- J. Bellmunt
Medical Oncology, Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA
3 shared publications
Latest Publications
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e2021-e2022
Trends of lymphadenectomy in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: The impact of surgical technique
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e2021-e2022
Trends of lymphadenectomy in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: The impact of surgical technique
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e291-e292
Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy-based strategy for muscle-invasive urothelial carcinoma of the bladder
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e291-e292
Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy-based strategy for muscle-invasive urothelial carcinoma of the bladder
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e476-e478
Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e476-e478
Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e2033-e2037
Robotic radical nephroureterectomy is associated with poorer oncological outcomes than open and laparoscopic radical nephroureterectomy
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e2033-e2037
Robotic radical nephroureterectomy is associated with poorer oncological outcomes than open and laparoscopic radical nephroureterectomy
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e2017-e2018
Comparing oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity match analysis
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e2017-e2018
Comparing oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity match analysis
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e295
Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e295
Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial
- 1 February 2017
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 48 (01) , 17-20
Drei Operationsmethoden bei Urothelkarzinom des distalen Ureters
Die radikale Nephroureterektomie (RNU) ist derzeit Standard bei der Behandlung von Urothelkarzinomen des oberen Harntrakts. Aufgrund des besseren onkologischen Outcomes sollte aber die distale Ureterektomie (DU) Mittel der ersten Wahl sein. Zu diesem Schluss kommen Seisen et al., die 3 verschiedene Operationsmethoden verglichen haben.
- 1 February 2017
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 48 (01) , 17-20
Drei Operationsmethoden bei Urothelkarzinom des distalen Ureters
Die radikale Nephroureterektomie (RNU) ist derzeit Standard bei der Behandlung von Urothelkarzinomen des oberen Harntrakts. Aufgrund des besseren onkologischen Outcomes sollte aber die distale Ureterektomie (DU) Mittel der ersten Wahl sein. Zu diesem Schluss kommen Seisen et al., die 3 verschiedene Operationsmethoden verglichen haben.
- 1 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e856
856 What is the impact of anticoagulant and antiplatelet treatment on peri-operative outcomes of robot-assisted partial nephrectomy?
- 1 March 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (3) , e856
856 What is the impact of anticoagulant and antiplatelet treatment on peri-operative outcomes of robot-assisted partial nephrectomy?
- 25 January 2016
- Published by Springer Nature in World Journal of Urology
- Vol. 35 (4) , 535-548
Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma
To review the contemporary data on the role of lymph node dissection (LND) at the time of radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). A computerized bibliographic search using the following protocol (“Nephroureterectomy”) AND (“Lymphadenectomy” OR “Lymph node” OR “Lymphatic”) was performed in MEDLINE to identify all original and review articles that addressed the role of LND for UTUC. Regional lymph node (LN) boundaries of UTUC have been recently investigated in mapping studies to propose anatomic templates of LND according to the laterality and location of primary tumor. Although these anatomic templates remained poorly described, most reports supported the staging benefit of LND that allowed for risk stratification of patients with (pN+) or without (pN0) LN metastases from those who did not undergo such a procedure (pNx). In addition, the therapeutic benefit of LND at the time of RNU was supported by better oncological outcomes obtained after complete LND when compared to incomplete or no LND, especially in the group of patients with advanced disease. The number of LNs removed was also correlated with both, more accurate staging and greater cancer-specific survival after LND, whose feasibility and safety have been validated in prospective studies. Despite mostly based on data with level of evidence 3, our comprehensive review of the literature supports the staging and therapeutic benefits of LND at the time of RNU for UTUC, which are particularly significant for patients with muscle-invasive or locally advanced disease.
- 25 January 2016
- Published by Springer Nature in World Journal of Urology
- Vol. 35 (4) , 535-548
Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma
To review the contemporary data on the role of lymph node dissection (LND) at the time of radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). A computerized bibliographic search using the following protocol (“Nephroureterectomy”) AND (“Lymphadenectomy” OR “Lymph node” OR “Lymphatic”) was performed in MEDLINE to identify all original and review articles that addressed the role of LND for UTUC. Regional lymph node (LN) boundaries of UTUC have been recently investigated in mapping studies to propose anatomic templates of LND according to the laterality and location of primary tumor. Although these anatomic templates remained poorly described, most reports supported the staging benefit of LND that allowed for risk stratification of patients with (pN+) or without (pN0) LN metastases from those who did not undergo such a procedure (pNx). In addition, the therapeutic benefit of LND at the time of RNU was supported by better oncological outcomes obtained after complete LND when compared to incomplete or no LND, especially in the group of patients with advanced disease. The number of LNs removed was also correlated with both, more accurate staging and greater cancer-specific survival after LND, whose feasibility and safety have been validated in prospective studies. Despite mostly based on data with level of evidence 3, our comprehensive review of the literature supports the staging and therapeutic benefits of LND at the time of RNU for UTUC, which are particularly significant for patients with muscle-invasive or locally advanced disease.
- 1 April 2015
- Published by Elsevier in European Urology Supplements
- Vol. 14 (2) , e1056-e1056a
1056 Detection of FGFR3 mutations from urine sediment DNA to predict the risk of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma
- 1 April 2015
- Published by Elsevier in European Urology Supplements
- Vol. 14 (2) , e1056-e1056a
1056 Detection of FGFR3 mutations from urine sediment DNA to predict the risk of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma